logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis To Buy Back $5 Bln Shares - Quick Facts

Swiss pharma giant Novartis (NVS) on Friday announced the launch of a $5 billion share buyback, reflecting its confidence in its long-term growth prospects, as well as its commitment to deliver strong shareholder returns. The company said the buyback will start immediately and be executed over two years on the 2nd trading line.

The company noted that it re-confirmed its capital structure aligned with a target rating of double-A as a reflection of its financial strength and discipline. It will allocate capital to a strong and growing dividend, value-creating bolt-on acquisitions and a $5 billion share buyback starting immediately.

The firm also announced it will continue to pursue an aggressive productivity agenda, which has offset generic erosion and growth investments over the past two years. Ongoing initiatives include leveraging scale in Procurement, consolidating Research sites around the world and optimizing the manufacturing footprint.

The company expects that the programs will deliver approximately 3-4% of sales in productivity gains per year through 2015, and contribute to organic margin leverage.

According to the company, Pharmaceuticals, the largest division in the company portfolio is preparing for a new growth phase, driven by an expanding blockbuster portfolio and an industry-leading pipeline. In addition to products with blockbuster status such as Lucentis, Gilenya, Afinitor and Tasigna, the Galvus group is expected to reach more than $1 billion in net sales by year end and there is the potential for a total of 14 or more blockbusters by 2018.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT